Cozowicz Crispiana, Zhong Haoyan, Illescas Alex, Athanassoglou Vassilis, Poeran Jashvant, Reichel Julia Frederica, Poultsides Lazaros A, Liu Jiabin, Memtsoudis Stavros G
From the Department of Anesthesiology, Perioperative Medicine and Intensive Care Medicine, Paracelsus Medical University, Salzburg, Austria.
Department of Anesthesiology, Critical Care and Pain Management, Hospital for Special Surgery, Weill Cornell Medical College, New York, New York.
Anesth Analg. 2022 Mar 1;134(3):486-495. doi: 10.1213/ANE.0000000000005854.
Despite numerous indications for perioperative benzodiazepine use, associated risks may be exacerbated in elderly and comorbid patients. In the absence of national utilization data, we aimed to describe utilization patterns using national claims data from total hip/knee arthroplasty patients (THA/TKA), an increasingly older and vulnerable surgical population.
We included data on 1,863,996 TKAs and 985,471 THAs (Premier Healthcare claims data, 2006-2019). Benzodiazepine utilization (stratified by long- and short-acting agents) was assessed by patient- and health care characteristics, and analgesic regimens. Given the large sample size, standardized differences instead of P values were utilized to signify meaningful differences between groups (defined by value >0.1).
Among 1,863,996 TKA and 985,471 THA patients, the utilization rate of benzodiazepines was 80.5% and 76.1%, respectively. In TKA, 72.6% received short-acting benzodiazepines, while 7.9% received long-acting benzodiazepines, utilization rates 68.4% and 7.7% in THA, respectively. Benzodiazepine use was particularly more frequent among younger patients (median age [interquartile range {IQR}]: 66 [60-73]/64 [57-71] among short/long-acting compared to 69 [61-76] among nonusers), White patients (80.6%/85.4% short/long-acting versus 75.7% among nonusers), commercial insurance (36.5%/34.0% short/long-acting versus 29.1% among nonusers), patients receiving neuraxial anesthesia (56.9%/56.5% short/long-acting versus 51.5% among nonusers), small- and medium-sized (≤500 beds) hospitals (68.5% in nonusers, and 74% and 76.7% in short- and long-acting benzodiazepines), and those in the Midwest (24.6%/25.4% short/long-acting versus 16% among nonusers) in TKA; all standardized differences ≥0.1. Similar patterns were observed in THA except for race and comorbidity burden. Notably, among patients with benzodiazepine use, in-hospital postoperative opioid administration (measured in oral morphine equivalents [OMEs]) was substantially higher. This was even more pronounced in patients who received long-acting agents (median OME with no benzodiazepines utilization 192 [IQR, 83-345] vs 256 [IQR, 153-431] with short-acting, and 329 [IQR, 195-540] with long-acting benzodiazepine administration). Benzodiazepine use was also more frequent in patients receiving multimodal analgesia (concurrently 2 or more analgesic modes) and regional anesthesia. Trend analysis showed a persistent high utilization rate of benzodiazepines over the last 14 years.
Based on a representative sample, 4 of 5 patients undergoing major orthopedic surgery in the United States receive benzodiazepines perioperatively, despite concerns for delirium and delayed postoperative neurocognitive recovery. Notably, benzodiazepine utilization was coupled with substantially increased opioid use, which may project implications for perioperative pain management.
尽管围手术期使用苯二氮䓬类药物有诸多指征,但在老年患者和合并症患者中,相关风险可能会加剧。由于缺乏全国性的使用数据,我们旨在利用全髋关节/膝关节置换术患者(THA/TKA)的全国索赔数据来描述使用模式,这是一个年龄越来越大且易受伤害的手术人群。
我们纳入了1,863,996例TKA和985,471例THA的数据(Premier医疗保健索赔数据,2006 - 2019年)。根据患者和医疗保健特征以及镇痛方案评估苯二氮䓬类药物的使用情况(按长效和短效药物分层)。鉴于样本量较大,采用标准化差异而非P值来表示组间的有意义差异(定义为值>0.1)。
在1,863,996例TKA和985,471例THA患者中,苯二氮䓬类药物的使用率分别为80.5%和76.1%。在TKA中,72.6%的患者接受短效苯二氮䓬类药物,而7.9%的患者接受长效苯二氮䓬类药物,在THA中的使用率分别为68.4%和7.7%。苯二氮䓬类药物在年轻患者(中位年龄[四分位间距{IQR}]:短效/长效使用者中为66岁[60 - 73岁]/64岁[57 - 71岁],非使用者为69岁[61 - 76岁])、白人患者(短效/长效使用者中为80.6%/85.4%,非使用者为75.7%)、商业保险患者(短效/长效使用者中为36.5%/34.0%,非使用者为29.1%)、接受神经轴索麻醉的患者(短效/长效使用者中为56.9%/56.5%,非使用者为51.5%)、中小型(≤500张床位)医院的患者(非使用者中为68.5%,短效和长效苯二氮䓬类药物使用者中分别为74%和76.7%)以及中西部地区的患者(TKA中短效/长效使用者中为24.6%/25.4%,非使用者为16%)中使用更为频繁;所有标准化差异≥0.1。在THA中观察到类似模式,但种族和合并症负担除外。值得注意的是,在使用苯二氮䓬类药物的患者中,术后住院期间阿片类药物的使用量(以口服吗啡当量[OMEs]衡量)显著更高。在接受长效药物的患者中更为明显(未使用苯二氮䓬类药物的患者中位OMEs为192[IQR,83 - 345],短效使用者为256[IQR,153 - 431],长效苯二氮䓬类药物使用者为329[IQR,195 - 540])。在接受多模式镇痛(同时使用2种或更多镇痛模式)和区域麻醉的患者中,苯二氮䓬类药物的使用也更为频繁。趋势分析显示,在过去14年中苯二氮䓬类药物的使用率持续居高不下。
基于一个具有代表性的样本,在美国,五分之四接受大型骨科手术的患者在围手术期使用苯二氮䓬类药物,尽管存在谵妄和术后神经认知恢复延迟的担忧。值得注意的是,苯二氮䓬类药物的使用与阿片类药物使用的大幅增加相关,这可能对围手术期疼痛管理产生影响。